Raf-1 Antibody
| Code | Size | Price |
|---|
| PSI-79-697-0.1mg | 0.1mg | £481.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Application: Western Blot (WB)
Storage:
Store antibody at -20˚C for up to one year.
Documents
Further Information
Additional Names:
Raf, c-RAF, RAF proto-oncogene serine/threonine-protein kinase
Application Note:
Western Blot: 1:500~1:1000
Background:
A-Raf, B-Raf and c-Raf (Raf-1) are the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway (1). Activation of c-Raf is the best understood and involves phosphorylation at multiple activating sites including Ser338, Tyr341, Thr491, Ser494, Ser497 and Ser499 (2). p21-activated protein kinase (PAK) has been shown to phosphorylate c-Raf at Ser338 and the Src family phosphorylates Tyr341 to induce c-Raf activity (3, 4). Ser338 of c-Raf corresponds to similar sites in A-Raf (Ser299) and B-Raf (Ser445), although this site is constitutively phosphorylated in B-Raf (5). Inhibitory 14-3-3 binding sites on c-Raf (Ser259 and Ser621) can be phosphorylated by Akt and AMPK, respectively (6, 7). While A-Raf, B-Raf and c-Raf are similar in sequence and function, differential regulation has been observed (8). Of particular interest, B-Raf contains three consensus Akt phosphorylation sites (Ser364, Ser428 and Thr439) and lacks a site equivalent to Tyr341 of c-Raf (8, 9). The B-Raf mutation V600E results in elevated kinase activity and is commonly found in malignant melanoma (10). Six residues of c-Raf (Ser29, Ser43, Ser289, Ser296, Ser301 and Ser642) become hyperphosphorylated in a manner consistent with c-Raf inactivation. The hyperphosphorylation of these six sites is dependent on downstream MEK signaling and renders c-Raf unresponsive to
Background References:
- Avruch, J. et al. (1994) Trends Biochem. Sci. 19, 279-283. Chong, H. et al. (2001) EMBO J. 20, 3716-3727. King, A. J. et al. (1998) Nature 396, 180-183. Fabian, J. R. et al. (1993) Mol. Cell Biol. 13, 7170-7179. Mason, C. S. et al. (1999) EMBO J. 18, 2137-2148. Zimmermann, S. and Moelling, K. (1999) Science 286, 1741-1744. Sprenkle, A. B. et al. (1997) FEBS Lett. 403, 254-258. Marais, R. et al. (1997) J. Biol. Chem. 272, 4378-4383. Guan, K. L. et al. (2000) J. Biol. Chem. 275, 27354-27359. Davies, H. et al. (2002) Nature 417, 949-954. Dougherty, M. K. et al. (2005) Mol. Cell 17, 215-224.
Buffer:
Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Raf-1 antibody was raised against a peptide sequence around aa. 641-645 (T-S-P-R-L ) derived from Rat Raf-1.
NCBI Gene ID #:
24703
NCBI Official Name:
v-raf-leukemia viral oncogene 1
NCBI Official Symbol:
Raf1
NCBI Organism:
This antibody was raised against a peptide sequence around aa. 641-645 (T-S-P-R-L ) derived from Rat Raf-1.
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
74 kDa
Protein Accession #:
NP_036771.1
Protein GI Number:
6981458
Purification:
Antibodies were purified by affinity-chromatography using epitope-specific peptide
Research Area:
Other
SPECIFICITY:
This antibody detects endogenous level of total Raf-1 protein.
Swissprot #:
P11345